|
| |
This
graph demonstrates the potential for
evidence-based use of diagnostics to
improve
health care quality and to avoid unnecessary
adverse health events, deaths, and costs.**
|
|
|
| HEDIS Quality
Measure
|
Percent National Under-use in HEDIS Compliant Health
Plans |
Estimated Annual Avoidable
Adverse Health Events |
Estimated Annual Avoidable Deaths
16,000 - 33,900 |
Estimated Annual Avoidable Costs
$899 million |
| Breast cancer
screening (biopsy,
needle aspiration or mammography)
|
19.3% |
7,600 breast cancer cases treated in Stage IV due to late diagnosis |
600 - 1,000 |
$ 48 million |
| Cholesterol management |
48.9 |
14,600 major coronary events |
6,900 - 17,000 |
$ 87 million |
| Colorectal cancer
screening (FOBT or colonoscopy)
|
51.9 |
20,000 cases of colorectal cancer diagnosed/treated at a later stage
|
4,200 - 6,300 |
$191 million |
| Diabetes management
(HbA1c control) |
20.2 |
14,000 heart attacks, strokes, or amputations |
4,300 - 9,600 |
$573 million |
|
*Source:
The state of health care quality:
industry trends and analysis. Washington,
DC: National Committee for Quality
Assurance, 2004.
**This
Data does not include statistics
for the uninsured.
Click
here to
view the study, "The Value
of Diagnostics Innovation, Adoption,
and Diffusion into Health Care."
|
|
| |
|
|
|
|
| |
|
|
|
|
